Brain tumors

Pediatric PET Imaging

Volumn , Issue , 2006, Pages 175-219

  Fisher, Michael J ^a   Phillips, Peter C ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84889962567     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/0-387-34641-4_11     Document Type: Chapter

References (180)

1. Di Chiro G, DeLaPaz RL, Brooks RA, et al. Glucose utilization of cerebral gliomas measured by [18F] fluorodeoxyglucose and positron emission tomography. Neurology 1982;32:1323-1329.
2. Wong TZ, van der Westhuizen GJ, Coleman RE. Positron emission tomography imaging of brain tumors. Neuroimaging Clin North Am 2002; 12:615-626.
3. Schaller B. Usefulness of positron emission tomography in diagnosis and treatment follow-up of brain tumors. Neurobiol Dis 2004;15:437-448.
4. Kim CK, Alavi JB, Alavi A, et al. New grading system of cerebral gliomas using positron emission tomography with F-18 fluorodeoxyglucose. J Neurooncol 1991;10:85-91.
5. Meyer PT, Schreckenberger M, Spetzger U, et al. Comparison of visual and ROI-based brain tumour grading using 18F-FDG PET: ROC analyses. Eur J Nucl Med 2001;28:165-174.
6. Hustinx R, Smith RJ, Benard F, et al. Can the standardized uptake value characterize primary brain tumors on FDG-PET? Eur J Nucl Med 1999; 26:1501-1509.
7. Hoekstra CJ, Paglianiti I, Hoekstra OS, et al. Monitoring response to therapy in cancer using [18F]-2-fluoro-2-deoxy-D-glucose and positron emission tomography: An overview of different analytical methods. Eur J Nucl Med 2000;27:731-743.
8. Massager N, David P, Goldman S, et al. Combined magnetic resonance imaging-and positron emission tomography-guided stereotactic biopsy in brainstem mass lesions: Diagnostic yield in a series of 30 patients. J Neurosurg 2000;93:951-957.
9. Buchler T, Cervinek L, Belohlavek O, et al. Langerhans cell histiocytosis with central nervous system involvement: follow-up by FDG-PET during treatment with cladribine. Pediatr Blood Cancer 2005;44:286-288.
10. Rosenfeld SS, Hoffman JM, Coleman RE, et al. Studies of primary central nervous system lymphoma with fluorine-18-fluorodeoxyglucose positron emission tomography. J Nucl Med 1992;33:532-536.
11. Hoffman JM, Waskin HA, Schifter T, et al. FDG-PET in differentiating lymphoma from nonmalignant central nervous system lesions in patients with AIDS. J Nucl Med 1993;34:567-575.
12. Pierce MA, Johnson MD, Maciunas RJ, et al. Evaluating contrastenhancing brain lesions in patients with AIDS by using positron emission tomography. Ann Intern Med 1995;123:594-598.
13. Heald AE, Hoffman JM, Bartlett JA, et al. Differentiation of central nervous system lesions in AIDS patients using positron emission tomography (PET). Int J STD AIDS 1996;7:337-346.
14. O'Doherty MJ, Barrington SF, Campbell M, et al. PET scanning and the human immunodeficiency virus-positive patient. J Nucl Med 1997;38: 1575-1583.
15. Villringer K, Jager H, Dichgans M, et al. Differential diagnosis of CNS lesions in AIDS patients by FDG-PET. J Comput Assist Tomogr 1995;19:532-536.
16. Roelcke U, Leenders KL. Positron emission tomography in patients with primary CNS lymphomas. J Neurooncol 1999;43:231-236.
17. Marom EM, McAdams HP, Erasmus JJ, et al. Staging non-small cell lung cancer with whole-body PET. Radiology 1999;212:803-809.
18. Griffeth LK, Rich KM, Dehdashti F, et al. Brain metastases from non-central nervous system tumors: evaluation with PET. Radiology 1993;186:37-44.
19. Larcos G, Maisey MN. FDG-PET screening for cerebral metastases in patients with suspected malignancy. Nucl Med Commun 1996;17:197-198.
20. Rohren EM, Provenzale JM, Barboriak DP, et al. Screening for cerebral metastases with FDG PET in patients undergoing whole-body staging of non-central nervous system malignancy. Radiology 2003;226:181-187.
21. Barker FG, 2nd Chang SM, Valk PE, et al. 18-Fluorodeoxyglucose uptake and survival of patients with suspected recurrent malignant glioma.Cancer 1997;79:115-126.
22. Choi SJ, Kim JS, Kim JH, et al. [18F]3?-deoxy-3?-fluorothymidine PET for the diagnosis and grading of brain tumors. Eur J Nucl Med Mol Imaging 2005;32:653-659.
23. De Witte O, Levivier M, Violon P, et al. Prognostic value positron emission tomography with [18F]fluoro-2-deoxy-d-glucose in the low-grade glioma. Neurosurgery 1996;39:470-476; discussion 476-477.
24. Kaschten B, Stevenaert A, Sadzot B, et al. Preoperative evaluation of 54 gliomas by PET with fluorine-18-fluorodeoxyglucose and/or carbon-11-methionine. J Nucl Med 1998;39:778-785.
25. Levivier M, Goldman S, Pirotte B, et al. Diagnostic yield of stereotactic brain biopsy guided by positron emission tomography with [18F] fluorodeoxyglucose. J Neurosurg 1995;82:445-452.
26. Ohtani T, Kurihara H, Ishiuchi S, et al. Brain tumour imaging with carbon-11 choline: comparison with FDG PET and gadolinium-enhanced MR imaging. Eur J Nucl Med 2001;28:1664-1670.
27. Pirotte B, Goldman S, Massager N, et al. Combined use of 18F-fluorodeoxyglucose and 11C-methionine in 45 positron emission tomographyguided stereotactic brain biopsies. J Neurosurg 2004;101:476-483.
28. Kaplan AM, Bandy DJ, Manwaring KH, et al. Functional brain mapping using positron emission tomography scanning in preoperative neurosurgical planning for pediatric brain tumors. J Neurosurg 1999;91:797-803.
29. Duncan JD, Moss SD, Bandy DJ, et al. Use of positron emission tomography for presurgical localization of eloquent brain areas in children with seizures. Pediatr Neurosurg 1997;26:144-156.
30. Borgwardt L, Hojgaard L, Carstensen H, et al. Increased fluorine-18 2-fluoro-2-deoxy-d-glucose (FDG) uptake in childhood CNS tumors is correlated with malignancy grade: A study with FDG positron emission tomography/magnetic resonance imaging coregistration and image fusion. J Clin Oncol 2005;23:3030-3037.
31. Plowman PN, Saunders CA, Maisey M. On the usefulness of brain PET scanning to the paediatric neuro-oncologist. Br J Neurosurg 1997;11: 525-532.
32. Holthoff VA, Herholz K, Berthold F, et al. In vivo metabolism of childhood posterior fossa tumors and primitive neuroectodermal tumors before and after treatment. Cancer 1993;72:1394-1403.
33. Hoffman JM, Hanson MW, Friedman HS, et al. FDG-PET in pediatric posterior fossa brain tumors. J Comput Assist Tomogr 1992;16:62-68.
34. Mineura K, Yasuda T, Kowada M, et al. Positron emission tomographic evaluations in the diagnosis and therapy of multifocal glioblastoma. Report of a pediatric case. Pediatr Neurosci 1985;12:208-212.
35. Bruggers CS, Friedman HS, Fuller GN, et al. Comparison of serial PET and MRI scans in a pediatric patient with a brainstem glioma. Med Pediatr Oncol 1993;21:301-306.
36. Molloy PT, Defeo R, Hunter J, et al. Excellent correlation of FDG-PET imaging with clinical outcome in patients with neurofibromatosis type I and low grade astrocytomas. J Nucl Med 1999;40:129P.
37. Fulham MJ, Brunetti A, Aloj L, et al. Decreased cerebral glucose metabolism in patients with brain tumors: An effect of corticosteroids. J Neurosurg 1995;83:657-664.
38. Glantz MJ, Hoffman JM, Coleman RE, et al. Identification of early recurrence of primary central nervous system tumors by [18F]fluorodeoxyglucose positron emission tomography. Ann Neurol 1991;29:347-355.
39. Roelcke U, Blasberg RG, von Ammon K, et al. Dexamethasone treatment and plasma glucose levels: relevance for fluorine-18-fluorodeoxyglucose uptake measurements in gliomas. J Nucl Med 1998;39:879-884.
40. Ishizu K, Nishizawa S, Yonekura Y, et al. Effects of hyperglycemia on FDG uptake in human brain and glioma. J Nucl Med 1994;35:1104-1109.
41. Spence AM, Muzi M, Mankoff DA, et al. 18F-FDG PET of gliomas at delayed intervals: Improved distinction between tumor and normal gray matter. J Nucl Med 2004;45:1653-1659.
42. Jager PL, Vaalburg W, Pruim J, et al. Radiolabeled amino acids: basic aspects and clinical applications in oncology. J Nucl Med 2001;42:432-445.
43. Ishiwata K, Kubota K, Murakami M, et al. Re-evaluation of amino acid PET studies: can the protein synthesis rates in brain and tumor tissues be measured in vivo? J Nucl Med 1993;34:1936-1943.
44. Nuutinen J, Sonninen P, Lehikoinen P, et al. Radiotherapy treatment planning and long-term follow-up with [(11)C]methionine PET in patients with low-grade astrocytoma. Int J Radiat Oncol Biol Phys 2000;48:43-52.
45. Herholz K, Holzer T, Bauer B, et al. 11C-methionine PET for differential diagnosis of low-grade gliomas. Neurology 1998;50:1316-1322.
46. Mosskin M, Bergstrom M, Collins VP, et al. Positron emission tomography with 11C-methionine of intracranial tumours compared with histology of multiple biopsies. Acta Radiol Suppl 1986;369:157-160.
47. Bergstrom M, Collins VP, Ehrin E, et al. Discrepancies in brain tumor extent as shown by computed tomography and positron emission tomography using [68Ga]EDTA, [11C]glucose, and [11C]methionine. J Comput Assist Tomogr 1983;7:1062-1066.
48. Ogawa T, Shishido F, Kanno I, et al. Cerebral glioma: evaluation with methionine PET. Radiology 1993;186:45-53.
49. De Witte O, Goldberg I, Wikler D, et al. Positron emission tomography with injection of methionine as a prognostic factor in glioma. J Neurosurg 2001;95:746-750.
50. Chung JK, Kim YK, Kim SK, et al. Usefulness of 11C-methionine PET in the evaluation of brain lesions that are hypo-or isometabolic on 18F-FDG PET. Eur J Nucl Med Mol Imaging 2002;29:176-182.
51. Nakagawa M, Kuwabara Y, Sasaki M, et al. 11C-methionine uptake in cerebrovascular disease: A comparison with 18F-FDG PET and 99mTc-HMPAO SPECT. Ann Nucl Med 2002;16:207-211.
52. Pruim J, Willemsen AT, Molenaar WM, et al. Brain tumors: L-[1-C-11] tyrosine PET for visualization and quantification of protein synthesis rate. Radiology 1995;197:221-226.
53. Ogawa T, Inugami A, Hatazawa J, et al. Clinical positron emission tomography for brain tumors: comparison of fludeoxyglucose F 18 and L-methyl-11C-methionine. AJNR 1996;17:345-353.
54. Pirotte B, Goldman S, David P, et al. Stereotactic brain biopsy guided by positron emission tomography (PET) with [F-18]fluorodeoxyglucose and [C-11]methionine. Acta Neurochir Suppl 1997;68:133-138.
55. Sasaki M, Kuwabara Y, Yoshida T, et al. A comparative study of thallium-201 SPET, carbon-11 methionine PET and fluorine-18 fluorodeoxyglucose PET for the differentiation of astrocytic tumours. Eur J Nucl Med 1998; 25:1261-1269.
56. Derlon JM, Petit-Taboue MC, Chapon F, et al. The in vivo metabolic pattern of low-grade brain gliomas: A positron emission tomographic study using 18F-fluorodeoxyglucose and 11C-l-methylmethionine. Neurosurgery 1997;40:276-287; discussion 287-288.
57. O'Tuama LA, Phillips PC, Strauss LC, et al. Two-phase [11C]L-methionine PET in childhood brain tumors. Pediatr Neurol 1990;6:163-170.
58. Utriainen M, Metsahonkala L, Salmi TT, et al. Metabolic characterization of childhood brain tumors: comparison of 18F-fluorodeoxyglucose and 11C-methionine positron emission tomography. Cancer 2002;95: 1376-1386.
59. Di Chiro G. Positron emission tomography using [18F] fluorodeoxyglucose in brain tumors. A powerful diagnostic and prognostic tool. Invest Radiol 1987;22:360-371.
60. Patronas NJ, Brooks RA, De La Paz RL, et al. Glycolytic rate (PET) and contrast enhancement (CT) in human cerebral gliomas. AJNR 1983;4: 533-535.
61. Delbeke D, Meyerowitz C, Lapidus RL, et al. Optimal cutoff levels of F-18 fluorodeoxyglucose uptake in the differentiation of low-grade from high-grade brain tumors with PET. Radiology 1995;195:47-52.
62. Goldman S, Levivier M, Pirotte B, et al. Regional glucose metabolism and histopathology of gliomas. A study based on positron emission tomography-guided stereotactic biopsy. Cancer 1996;78:1098-1106.
63. Padma MV, Said S, Jacobs M, et al. Prediction of pathology and survival by FDG PET in gliomas. J Neurooncol 2003;64:227-237.
64. Fulham MJ, Melisi JW, Nishimiya J, et al. Neuroimaging of juvenile pilocytic astrocytomas: An enigma. Radiology 1993;189:221-225.
65. Roelcke U, Radu EW, Hausmann O, et al. Tracer transport and metabolism in a patient with juvenile pilocytic astrocytoma. A PET study. J Neurooncol 1998;36:279-283.
66. Hustinx R, Alavi A. SPECT and PET imaging of brain tumors. Neuroimaging Clin North Am 1999;9:751-766.
67. Kleihues P, Kavanee WK. Pathology and Genetics. Tumours of the Nervous System. Lyon: IARC Press, 2000.
68. Derlon JM, Bourdet C, Bustany P, et al. [11C]L-methionine uptake in gliomas. Neurosurgery 1989;25:720-728.
69. Sato N, Suzuki M, Kuwata N, et al. Evaluation of the malignancy of glioma using 11C-methionine positron emission tomography and proliferating cell nuclear antigen staining. Neurosurg Rev 1999;22:210-214.
70. Ribom D, Engler H, Blomquist E, et al. Potential significance of (11)Cmethionine PET as a marker for the radiosensitivity of low-grade gliomas. Eur J Nucl Med Mol Imaging 2002;29:632-640.
71. Derlon JM, Chapon F, Noel MH, et al. Non-invasive grading of oligodendrogliomas: correlation between in vivo metabolic pattern and histopathology. Eur J Nucl Med 2000;27:778-787.
72. Patronas NJ, Di Chiro G, Kufta C, et al. Prediction of survival in glioma patients by means of positron emission tomography. J Neurosurg 1985; 62:816-822.
73. Alavi JB, Alavi A, Chawluk J, et al. Positron emission tomography in patients with glioma. A predictor of prognosis. Cancer 1988;62: 1074-1078.
74. Holzer T, Herholz K, Jeske J, et al. FDG-PET as a prognostic indicator in radiochemotherapy of glioblastoma. J Comput Assist Tomogr 1993;17: 681-687.
75. Schifter T, Hoffman JM, Hanson MW, et al. Serial FDG-PET studies in the prediction of survival in patients with primary brain tumors. J Comput Assist Tomogr 1993;17:509-561.
76. Pardo FS, Aronen HJ, Fitzek M, et al. Correlation of FDG-PET interpretation with survival in a cohort of glioma patients. Anticancer Res 2004;24:2359-2365.
77. Spence AM, Muzi M, Graham MM, et al. 2-[(18)F]Fluoro-2-deoxyglucose and glucose uptake in malignant gliomas before and after radiotherapy: correlation with outcome. Clin Cancer Res 2002;8:971-979.
78. De Witte O, Lefranc F, Levivier M, et al. FDG-PET as a prognostic factor in high-grade astrocytoma. J Neurooncol 2000;49:157-163.
79. Francavilla TL, Miletich RS, Di Chiro G, et al. Positron emission tomography in the detection of malignant degeneration of low-grade gliomas. Neurosurgery 1989;24:1-5.
80. Di Chiro G, Hatazawa J, Katz DA, et al. Glucose utilization by intracranial meningiomas as an index of tumor aggressivity and probability of recurrence: A PET study. Radiology 1987;164:521-526.
81. Janus TJ, Kim EE, Tilbury R, et al. Use of [18F]fluorodeoxyglucose positron emission tomography in patients with primary malignant brain tumors. Ann Neurol 1993;33:540-548.
82. Mogard J, Kihlstrom L, Ericson K, et al. Recurrent tumor vs radiation effects after gamma knife radiosurgery of intracerebral metastases: Diagnosis with PET-FDG. J Comput Assist Tomogr 1994;18:177-181.
83. Ericson K, Kihlstrom L, Mogard J, et al. Positron emission tomography using 18F-fluorodeoxyglucose in patients with stereotactically irradiated brain metastases. Stereotact Funct Neurosurg 1996;66 Suppl 1:214-224.
84. Ribom D, Eriksson A, Hartman M, et al. Positron emission tomography (11)C-methionine and survival in patients with low-grade gliomas. Cancer 2001;92:1541-1549.
85. Paulus W, Peiffer J. Intratumoral histologic heterogeneity of gliomas. A quantitative study. Cancer 1989;64:442-447.
86. Floeth FW, Pauleit D, Wittsack HJ, et al. Multimodal metabolic imaging of cerebral gliomas: positron emission tomography with [18F]fluoroethyll-tyrosine and magnetic resonance spectroscopy. J Neurosurg 2005;102: 318-327.
87. Hanson MW, Glantz MJ, Hoffman JM, et al. FDG-PET in the selection of brain lesions for biopsy. J Comput Assist Tomogr 1991;15:796-801.
88. Thomas DG, Gill SS, Wilson CB, et al. Use of relocatable stereotactic frame to integrate positron emission tomography and computed tomography images: Application in human malignant brain tumours. Stereotact Funct Neurosurg 1990;54-55:388-392.
89. Pirotte B, Goldman S, Brucher JM, et al. PET in stereotactic conditions increases the diagnostic yield of brain biopsy. Stereotact Funct Neurosurg 1994;63:144-149.
90. Levivier M, Wikler D Jr, Massager N, et al. The integration of metabolic imaging in stereotactic procedures including radiosurgery: A review. J Neurosurg 2002;97:542-550.
91. Thiel A, Pietrzyk U, Sturm V, et al. Enhanced accuracy in differential diagnosis of radiation necrosis by positron emission tomography-magnetic resonance imaging coregistration: Technical case report. Neurosurgery 2000;46:232-234.
92. Pirotte B, Goldman S, Salzberg S, et al. Combined positron emission tomography and magnetic resonance imaging for the planning of stereotactic brain biopsies in children: experience in 9 cases. Pediatr Neurosurg 2003;38:146-155.
93. Maruyama I, Sadato N, Waki A, et al. Hyperacute changes in glucose metabolism of brain tumors after stereotactic radiosurgery: A PET study. J Nucl Med 1999;40:1085-1090.
94. De Witte O, Hildebrand J, Luxen A, et al. Acute effect of carmustine on glucose metabolism in brain and glioblastoma. Cancer 1994;74: 2836-2842.
95. Spence AM, Mankoff DA, Muzi M. Positron emission tomography imaging of brain tumors. Neuroimaging Clin North Am 2003;13:717-739.
96. Widnell CC, Baldwin SA, Davies A, et al. Cellular stress induces a redistribution of the glucose transporter. Faseb J 1990;4:1634-1637.
97. Sviderskaya EV, Jazrawi E, Baldwin SA, et al. Cellular stress causes accumulation of the glucose transporter at the surface of cells independently of their insulin sensitivity. J Membr Biol 1996;149:133-140.
98. Haberkorn U, Morr I, Oberdorfer F, et al. Fluorodeoxyglucose uptake in vitro: Aspects of method and effects of treatment with gemcitabine. J Nucl Med 1994;35:1842-1850.
99. Haberkorn U, Oberdorfer F, Klenner T, et al. Metabolic and transcriptional changes in osteosarcoma cells treated with chemotherapeutic drugs. Nucl Med Biol 1994;21:835-845.
100. Haberkorn U, Bellemann ME, Altmann A, et al. PET 2-fluoro-2-deoxyglucose uptake in rat prostate adenocarcinoma during chemotherapy with gemcitabine. J Nucl Med 1997;38:1215-1221.
101. Fujibayashi Y, Waki A, Sakahara H, et al. Transient increase in glycolytic metabolism in cultured tumor cells immediately after exposure to ionizing radiation: from gene expression to deoxyglucose uptake. Radiat Res 1997;147:729-734.
102. Smith TA, Maisey NR, Titley JC, et al. Treatment of SW620 cells with Tomudex and oxaliplatin induces changes in 2-deoxy-d-glucose incorporation associated with modifications in glucose transport. J Nucl Med 2000;41:1753-1759.
103. Kubota R, Yamada S, Kubota K, et al. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med 1992;33:1972-1980.
104. Reinhardt MJ, Kubota K, Yamada S, et al. Assessment of cancer recurrence in residual tumors after fractionated radiotherapy: A comparison of fluorodeoxyglucose, L-methionine and thymidine. J Nucl Med 1997;38: 280-287.
105. Cokgor I, Akabani G, Kuan CT, et al. Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas. J Clin Oncol 2000;18:3862-3872.
106. Higashi K, Clavo AC, Wahl RL. In vitro assessment of 2-fluoro-2-deoxyd- glucose, L-methionine and thymidine as agents to monitor the early response of a human adenocarcinoma cell line to radiotherapy. J Nucl Med 1993;34:773-779.
107. Furuta M, Hasegawa M, Hayakawa K, et al. Rapid rise in FDG uptake in an irradiated human tumour xenograft. Eur J Nucl Med 1997;24:435-438.
108. Hasegawa M, Mitsuhashi N, Yamakawa M, et al. p53 protein expression and radiation-induced apoptosis in human tumors transplanted to nude mice. Radiat Med 1997;15:171-176.
109. Rozental JM, Levine RL, Mehta MP, et al. Early changes in tumor metabolism after treatment: The effects of stereotactic radiotherapy. Int J Radiat Oncol Biol Phys 1991;20:1053-1060.
110. Brock CS, Young H, O'Reilly SM, et al. Early evaluation of tumour metabolic response using [18F]fluorodeoxyglucose and positron emission tomography: A pilot study following the phase II chemotherapy schedule for temozolomide in recurrent high-grade gliomas. Br J Cancer 2000; 82:608-615.
111. Wang GJ, Volkow ND, Lau YH, et al. Glucose metabolic changes in nontumoral brain tissue of patients with brain tumor following radiotherapy: A preliminary study. J Comput Assist Tomogr 1996;20:709-714.
112. Bustany P, Chatel M, Derlon JM, et al. Brain tumor protein synthesis and histological grades: A study by positron emission tomography (PET) with C11-l-Methionine. J Neurooncol 1986;3:397-404.
113. Mineura K, Sasajima T, Kowada M, et al. [Changes in the (11C-methyl)-lmethionine uptake index in gliomas following radiotherapy]. Gan No Rinsho 1989;35:1101-1104.
114. Wurker M, Herholz K, Voges J, et al. Glucose consumption and methionine uptake in low-grade gliomas after iodine-125 brachytherapy. Eur J Nucl Med 1996;23:583-586.
115. Ogawa T, Kanno I, Hatazawa J, et al. Methionine PET for follow-up of radiation therapy of primary lymphoma of the brain. Radiographics 1994;14:101-110.
116. Heesters MA, Go KG, Kamman RL, et al. 11C-tyrosine position emission tomography and 1H magnetic resonance spectroscopy of the response of brain gliomas to radiotherapy. Neuroradiology 1998;40:103-108.
117. Patronas NJ, Di Chiro G, Brooks RA, et al. Work in progress: [18F] fluorodeoxyglucose and positron emission tomography in the evaluation of radiation necrosis of the brain. Radiology 1982;144:885-889.
118. Doyle WK, Budinger TF, Valk PE, et al. Differentiation of cerebral radiation necrosis from tumor recurrence by [18F]FDG and 82Rb positron emission tomography. J Comput Assist Tomogr 1987;11:563-570.
119. Di Chiro G, Oldfield E, Wright DC, et al. Cerebral necrosis after radiotherapy and/or intraarterial chemotherapy for brain tumors: PET and neuropathologic studies. AJR 1988;150:189-197.
120. Valk PE, Budinger TF, Levin VA, et al. PET of malignant cerebral tumors after interstitial brachytherapy. Demonstration of metabolic activity and correlation with clinical outcome. J Neurosurg 1988;69:830-838.
121. Langleben DD, Segall GM. PET in differentiation of recurrent brain tumor from radiation injury. J Nucl Med 2000;41:1861-1867.
122. Chao ST, Suh JH, Raja S, et al. The sensitivity and specificity of FDG PET in distinguishing recurrent brain tumor from radionecrosis in patients treated with stereotactic radiosurgery. Int J Cancer 2001;96:191-197.
123. Deshmukh A, Scott JA, Palmer EL, et al. Impact of fluorodeoxyglucose positron emission tomography on the clinical management of patients with glioma. Clin Nucl Med 1996;21:720-725.
124. Ricci PE, Karis JP, Heiserman JE, et al. Differentiating recurrent tumor from radiation necrosis: Time for re-evaluation of positron emission tomography? AJNR 1998;19:407-413.
125. Ogawa T, Kanno I, Shishido F, et al. Clinical value of PET with 18Ffluorodeoxyglucose and L-methyl-11C-methionine for diagnosis of recurrent brain tumor and radiation injury. Acta Radiol 1991;32:197-202.
126. Sonoda Y, Kumabe T, Takahashi T, et al. Clinical usefulness of 11C-MET PET and 201T1 SPECT for differentiation of recurrent glioma from radiation necrosis. Neurol Med Chir (Tokyo) 1998;38:342-347; discussion 347-348.
127. Tsuyuguchi N, Sunada I, Iwai Y, et al. Methionine positron emission tomography of recurrent metastatic brain tumor and radiation necrosis after stereotactic radiosurgery: Is a differential diagnosis possible? J Neurosurg 2003;98:1056-1064.
128. Tsuyuguchi N, Takami T, Sunada I, et al. Methionine positron emission tomography for differentiation of recurrent brain tumor and radiation necrosis after stereotactic radiosurgery-in malignant glioma. Ann Nucl Med 2004;18:291-296.
129. Tralins KS, Douglas JG, Stelzer KJ, et al. Volumetric analysis of 18F-FDG PET in glioblastoma multiforme: prognostic information and possible role in definition of target volumes in radiation dose escalation. J Nucl Med 2002;43:1667-1673.
130. Solberg TD, Agazaryan N, Goss BW, et al. A feasibility study of 18Ffluorodeoxyglucose positron emission tomography targeting and simultaneous integrated boost for intensity-modulated radiosurgery and radiotherapy. J Neurosurg 2004;101(suppl 3):381-389.
131. Miwa K, Shinoda J, Yano H, et al. Discrepancy between lesion distributions on methionine PET and MR images in patients with glioblastoma multiforme: Insight from a PET and MR fusion image study. J Neurol Neurosurg Psychiatry 2004;75:1457-1462.
132. Langen KJ, Jarosch M, Muhlensiepen H, et al. Comparison of fluorotyrosines and methionine uptake in F98 rat gliomas. Nucl Med Biol 2003; 30:501-508.
133. Wienhard K, Herholz K, Coenen HH, et al. Increased amino acid transport into brain tumors measured by PET of L-(2-18F)fluorotyrosine. J Nucl Med 1991;32:1338-1346.
134. Inoue T, Shibasaki T, Oriuchi N, et al. 18F alpha-methyl tyrosine PET studies in patients with brain tumors. J Nucl Med 1999;40:399-405.
135. Kaim AH, Weber B, Kurrer MO, et al. (18)F-FDG and (18)F-FET uptake in experimental soft tissue infection. Eur J Nucl Med Mol Imaging 2002; 29:648-654.
136. Rau FC, Weber WA, Wester HJ, et al. O-(2-[(18)F]Fluoroethyl)-l-tyrosine (FET): A tracer for differentiation of tumour from inflammation in murine lymph nodes. Eur J Nucl Med Mol Imaging 2002;29:1039-1046.
137. Weber WA, Wester HJ, Grosu AL, et al. O-(2-[18F]fluoroethyl)-l-tyrosine and L-[methyl-11C]methionine uptake in brain tumours: Initial results of a comparative study. Eur J Nucl Med 2000;27:542-549.
138. Pauleit D, Floeth F, Tellmann L, et al. Comparison of O-(2-18Ffluoroethyl)-l-tyrosine PET and 3-123I-iodo-alpha-methyl-l-tyrosine SPECT in brain tumors. J Nucl Med 2004;45:374-381.
139. Weckesser M, Langen KJ, Rickert CH, et al. O-(2-[(18)F]fluorethyl)-L: -tyrosine PET in the clinical evaluation of primary brain tumours. Eur J Nucl Med Mol Imaging 2005;32:422-429.
140. Messing-Junger AM, Floeth FW, Pauleit D, et al. Multimodal target point assessment for stereotactic biopsy in children with diffuse bithalamic astrocytomas. Childs Nerv Syst 2002;18:445-449.
141. Hubner KF, Thie JA, Smith GT, et al. Positron Emission Tomography (PET) with 1-aminocyclobutane-1-[(11)C]carboxylic acid (1-[(11)C]-ACBC) for detecting recurrent brain tumors. Clin Positron Imaging 1998;1:165-173.
142. O'Tuama LA, Guilarte TR, Douglass KH, et al. Assessment of [11C]-lmethionine transport into the human brain. J Cereb Blood Flow Metab 1988;8:341-345.
143. Becherer A, Karanikas G, Szabo M, et al. Brain tumour imaging with PET: A comparison between [18F]fluorodopa and [11C]methionine. Eur J Nucl Med Mol Imaging 2003;30:1561-1567.
144. Vander Borght T, Pauwels S, Lambotte L, et al. Brain tumor imaging with PET and 2-[carbon-11]thymidine. J Nucl Med 1994;35:974-982.
145. De Reuck J, Santens P, Goethals P, et al. [Methyl-11C]thymidine positron emission tomography in tumoral and non-tumoral cerebral lesions. Acta Neurol Belg 1999;99:118-125.
146. Eary JF, Mankoff DA, Spence AM, et al. 2-[C-11]thymidine imaging of malignant brain tumors. Cancer Res 1999;59:615-621.
147. Wells JM, Mankoff DA, Eary JF, et al. Kinetic analysis of 2-[11C] thymidine PET imaging studies of malignant brain tumors: preliminary patient results. Mol Imaging 2002;1:145-150.
148. Shields AF, Mankoff DA, Link JM, et al. Carbon-11-thymidine and FDG to measure therapy response. J Nucl Med 1998;39:1757-1762.
149. Wells JM, Mankoff DA, Muzi M, et al. Kinetic analysis of 2-[11C] thymidine PET imaging studies of malignant brain tumors: compartmental model investigation and mathematical analysis. Mol Imaging 2002;1: 151-159.
150. Tjuvajev J, Muraki A, Ginos J, et al. Iododeoxyuridine uptake and retention as a measure of tumor growth. J Nucl Med 1993;34:1152-1162.
151. Blasberg RG, Roelcke U, Weinreich R, et al. Imaging brain tumor proliferative activity with [124I]iododeoxyuridine. Cancer Res 2000;60: 624-635.
152. Liu RS. 31 Clinical application of Clin Positron Imaging 2000;3:185.
153. DeGrado TR, Baldwin SW, Wang S, et al. Synthesis and evaluation of (18)F-labeled choline analogs as oncologic PET tracers. J Nucl Med 2001; 42:1805-1814.
154. Hara T, Kosaka N, Shinoura N, et al. PET imaging of brain tumor with [methyl-11C]choline. J Nucl Med 1997;38:842-847.
155. Shinoura N, Nishijima M, Hara T, et al. Brain tumors: Detection with C-11 choline PET. Radiology 1997;202:497-503.
156. Utriainen M, Komu M, Vuorinen V, et al. Evaluation of brain tumor metabolism with [11C]choline PET and 1H-MRS. J Neurooncol 2003;62: 329-338.
157. Kwee SA, Coel MN, Lim J, et al. Combined use of F-18 fluorocholine positron emission tomography and magnetic resonance spectroscopy for brain tumor evaluation. J Neuroimaging 2004;14:285-289.
158. Hara T, Kondo T, Kosaka N. Use of 18F-choline and 11C-choline as contrast agents in positron emission tomography imaging-guided stereotactic biopsy sampling of gliomas. J Neurosurg 2003;99:474-479.
159. Mathias CJ, Welch MJ, Kilbourn MR, et al. Radiolabeled hypoxic cell sensitizers: Tracers for assessment of ischemia. Life Sci 1987;41:199-206.
160. Martin GV, Cerqueira MD, Caldwell JH, et al. Fluoromisonidazole. A metabolic marker of myocyte hypoxia. Circ Res 1990;67:240-244.
161. Tochon-Danguy HJ, Sachinidis JI, Chan F, et al. Imaging and quantitation of the hypoxic cell fraction of viable tumor in an animal model of intracerebral high grade glioma using [18F]fluoromisonidazole (FMISO). Nucl Med Biol 2002;29:191-197.
162. Valk PE, Mathis CA, Prados MD, et al. Hypoxia in human gliomas: Demonstration by PET with fluorine-18-fluoromisonidazole. J Nucl Med 1992;33:2133-2137.
163. Spence AM, Muzi M, Krohn KA. Molecular imaging of regional brain tumor biology. J Cell Biochem Suppl 2002;39:25-35.
164. Bergstrom M, Muhr C, Jossan S, et al. Differentiation of pituitary adenoma and meningioma: visualization with positron emission tomography and [11C]-L-deprenyl. Neurosurgery 1992;30:855-861.
165. Lucignani G, Losa M, Moresco RM, et al. Differentiation of clinically non-functioning pituitary adenomas from meningiomas and craniopharyngiomas by positron emission tomography with [18F]fluoroethyl-spiperone. Eur J Nucl Med 1997;24:1149-1155.
166. Junck L, Olson JM, Ciliax BJ, et al. PET imaging of human gliomas with ligands for the peripheral benzodiazepine binding site. Ann Neurol 1989;26:752-758.
167. Pappata S, Cornu P, Samson Y, et al. PET study of carbon-11-PK 11195 binding to peripheral type benzodiazepine sites in glioblastoma: A case report. J Nucl Med 1991;32:1608-1610.
168. Fredriksson A, Johnstrom P, Thorell JO, et al. In vivo evaluation of the biodistribution of 11C-labeled PD153035 in rats without and with neuroblastoma implants. Life Sci 1999;65:165-174.
169. Fisher MJ, Adamson PC. Anti-angiogenic agents for the treatment of brain tumors. Neuroimaging Clin North Am 2002;12:477-499.
170. Haubner R, Wester HJ, Weber WA, et al. Noninvasive imaging of alpha(v)beta3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res 2001;61: 1781-1785.
171. Haubner R, Weber WA, Beer AJ, et al. Noninvasive visualization of the activated alphavbeta3 integrin in cancer patients by positron emission tomography and [(18)F]galacto-RGD. PLoS Med 2005;2:e70.
172. Chen X, Park R, Shahinian AH, et al. 18F-labeled RGD peptide: Initial evaluation for imaging brain tumor angiogenesis. Nucl Med Biol 2004; 31:179-189.
173. Chen X, Park R, Hou Y, et al. MicroPET imaging of brain tumor angiogenesis with 18F-labeled PEGylated RGD peptide. Eur J Nucl Med Mol Imaging 2004;31:1081-1089.
174. Tjuvajev JG, Stockhammer G, Desai R, et al. Imaging the expression of transfected genes in vivo. Cancer Res 1995;55:6126-6132.
175. Tjuvajev JG, Finn R, Watanabe K, et al. Noninvasive imaging of herpes virus thymidine kinase gene transfer and expression: A potential method for monitoring clinical gene therapy. Cancer Res 1996;56:4087-4095.
176. Tjuvajev JG, Avril N, Oku T, et al. Imaging herpes virus thymidine kinase gene transfer and expression by positron emission tomography. Cancer Res 1998;58:4333-4341.
177. Murakami Y, Takamatsu H, Taki J, et al. 18F-labelled annexin V: A PET tracer for apoptosis imaging. Eur J Nucl Med Mol Imaging 2004;31: 469-474.
178. Yagle KJ, Eary JF, Tait JF, et al. Evaluation of 18F-annexin V as a PET imaging agent in an animal model of apoptosis. J Nucl Med 2005;46: 658-666.
179. Toretsky J, Levenson A, Weinberg IN, et al. Preparation of F-18 labeled annexin V: A potential PET radiopharmaceutical for imaging cell death. Nucl Med Biol 2004;31:747-752.
180. Saleem A, Brown GD, Brady F, et al. Metabolic activation of temozolomide measured in vivo using positron emission tomography. Cancer Res 2003;63:2409-2415.